Zidovudine Induces Visceral Mitochondrial Toxicity and Intra-Abdominal Fat Gain in a Rodent Model of Lipodystrophy

Abstract

Background

The use of zidovudine is associated with a loss of subcutaneous adipose tissue (SAT). We assessed if zidovudine treatment also affects visceral adipose tissue (VAT) and if uridine supplementation abrogates the adverse effects of zidovudine on VAT.

Methods

Rats were fed zidovudine for 21 weeks with or without simultaneous uridine supplementation. Control animals did not receive zidovudine, or were treated with uridine alone. Changes in SAT and VAT were monitored by magnetic resonance imaging. Adipose tissue was examined for structural and molecular signs of mitochondrial toxicity.

Results

Zidovudine induced lipoatrophy in SAT and fat hypertrophy in VAT. Compared with controls zidovudine-exposed VAT adipocytes had increased diameters, microvesicular steatosis and enlarged mitochondria with disrupted crystal architecture on electron microscopy. VAT adipocyte mitochondrial DNA (mtDNA) copy numbers were diminished, as were mtDNA-encoded respiratory chain proteins. The ‘common’ mtDNA deletion was detected in high frequencies in zidovudine treated animals, but not in the controls. Although mtDNA depletion was more profound in SAT compared with VAT, the ‘common’ deletion tended to be more frequent in the VAT than in the SAT. Uridine coadministration abrogated all effects of zidovudine on VAT and SAT pathology.

Conclusions

Zidovudine induces a gain of intra-abdominal fat in association with quantitative and qualitative alterations of the mitochondrial genome and impaired expression of mtDNA-encoded respiratory chain components, indicating that zidovudine may contribute to abdominal fat hypertrophy in HIV-infected patients. In this rodent model, uridine supplementation abrogates both SAT and VAT pathology induced by zidovudine.

References

Carr

, Cooper

D.A.

Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423–1430.

Nolan

, Hammond

, James

, McKinnon

, Mallal

Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8: 617–626.

Nolan

, Hammond

, Martin

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329–1338.

Alam

, Cortina-Borja

, Goetghebuer

Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr 2012; 59: 314–324.

Carr

, Samaras

, Chisholm

D.J.

, Cooper

D.A.

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881–1883.

Kakuda

T.N.

, Brundage

R.C.

, Anderson

P.L.

, Fletcher

C.V.

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 2311–2312.

Kakuda

T.N.

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685–708.

Caron

, Auclair

, Lagathu

The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18: 2127–2136.

Gattermann

, Dadak

, Hofhaus

Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1275–1279.

10.

Walker

U.A.

, Auclair

, Lebrecht

, Kornprobst

, Capeau

, Caron

Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11: 25–34.

11.

Setzer

, Lebrecht

, Walker

U.A.

Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 2008; 172: 681–690.

12.

McGee

K.C.

, Shahmanesh

, Boothby

Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones. Antivir Ther 2012; 17: 495–507.

13.

Mauss

, Berger

, Carls

, Schmutz

Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: a proof of principle?

AIDS 2003; 17: 944–945.

14.

van Vonderen

M.G.A.

, van Agtmael

M.A.

, Hassink

E.A.M.

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS ONE 2009; 4: e5647.

15.

Boothby

, McGee

K.C.

, Tomlinson

J.W.

Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther 2009; 14: 1089–1100.

16.

Feeney

E.R.

, van Vonderen

M.G.A.

, Wit

Zidovudine/ lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. AIDS 2012; 26: 2165–2174.

17.

Venhoff

, Zilly

, Lebrecht

Uridine pharmacokinetics of mitocnol, a sugar cane extract. AIDS 2005; 19: 739–740.

18.

Weinberg

M.E.

, Roman

M.C.

, Jacob

Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement. PLoS ONE 2011; 6: e14709.

19.

Collins

M.L.

, Sondel

, Cesar

, Hellerstein

M.K.

Effect of nucleoside reverse transcriptase inhibitors on mitochondrial DNA synthesis in rats and humans. J Acquir Immune Defic Syndr 2004; 37: 1132–1139.

20.

Lebrecht

, Setzer

, Ketelsen

U-P

, Haberstroh

, Walker

U.A.

Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003; 108: 2423–2429.

21.

Walker

U.A.

, Setzer

, Venhoff

Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165–2173.

22.

Schon

E.A.

, Rizzuto

, Moraes

C.T.

, Nakase

, Zeviani

, DiMauro

A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science 1989; 244: 346–349.

23.

Samuels

D.C.

, Schon

E.A.

, Chinnery

P.F.

Two direct repeats cause most human mtDNA deletions. Trends Genet 2004; 20: 393–398.

24.

Edris

, Burgett

, Stine

O.C.

, Filburn

C.R.

Detection and quantitation by competitive PCR of an age-associated increase in a 4.8-kb deletion in rat mitochondrial DNA. Mutat Res 1994; 316: 69–78.

25.

Lebrecht

, Kokkori

, Ketelsen

U P.

Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 2005; 207: 436–444.

26.

King

M P.

. Use of ethidium bromide to manipulate ratio of mutated and wild-type mitochondrial DNA in cultured cells. Methods Enzymol 1996; 264: 339–344.

27.

Walker

U.A.

, Bickel

, Lütke Volksbeck

S.I.

Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29: 117–121.

28.

Hammond

, Nolan

, James

, Metcalf

, Mallal

Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004; 18: 815–817.

29.

De Pauw

, Tejerina

, Raes

, Keijer

, Arnould

Mitochondrial (Dys)function in Adipocyte (De) differentiation and Systemic Metabolic Alterations. Am J Pathol 2009; 175: 927–939.

30.

Lafontan

, Berlan

Do regional differences in adipocyte biology provide new pathophysiological insights?

Trends Pharmacol Sci 2003; 24: 276–283.

31.

Deveaud

, Beauvoit

, Hagry

Site specific alterations of adipose tissue mitochondria in 3′-azido-3-'deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy?

Biochem Pharmacol 2005; 70: 90–101.

32.

Deveaud

, Beauvoit

, Salin

, Schaeffer

, Rigoulet

Regional differences in oxidative capacity of rat white adipose tissue are linked to the mitochondrial content of mature adipocytes. Mol Cell Biochem 2004; 267: 157–166.

33.

Benbrik

, Chariot

, Bonavaud

Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997; 149: 19–25.

34.

Stadhouders

A.M.

, Sengers

R.C.

Morphological observations in skeletal muscle from patients with a mitochondrial myopathy. J Inherit Metab Dis 1987; 10 Suppl 1: 62–80.

35.

Corral-Debrinski

, Stepien

, Shoffner

J.M.

Hypoxemia is associated with mitochondrial DNA damage and gene induction. JAMA 1991; 266: 1812–1816.

36.

Mazat

J.P.

, Rossignol

, Malgat

, Rocher

, Faustin

, Letellier

What do mitochondrial diseases teach us about normal mitochondrial functions…that we already knew: threshold expression of mitochondrial defects. Biochim Biophys Acta 2001; 1504: 20–30.

37.

Lenaz

, Baracca

, Carelli

, D'Aurelio

Bioenergetics of mitochondrial diseases associated with mtDNA mutations. Biochim Biophys Acta 2004; 1658: 89–94.

38.

Song

, Pursell

Z.F.

, Copeland

W.C.

, Longley

M.J.

, Kunkel

T.A.

, Mathews

C.K.

DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci U S A 2005; 102: 4990–4995.

39.

Song

, Wheeler

L.J.

, Mathews

C.K.

Deoxyribonucleotide pool imbalance stimulates deletions in HeLa cell mitochondrial DNA. J Biol Chem 2003; 278: 43893–43896.

40.

Giusti

, Suter

, Verdumo

, Gaillard

R.C.

, Burckhardt

, Pralong

F.P.

Molecular determinants of human adipose tissue: differences between visceral and subcutaneous compartments in obese women. J Clin Endocrinol Metab 2004; 89: 1379–1384.

41.

Barile

, Valenti

, Quagliariello

, Passarella

Mitochondria as cell targets of AZT (zidovudine). Gen Pharmacol 1998; 31: 531–538.

42.

Deveaud

, Beauvoit

, Reynaud

, Bonnet

Site-specific reduction of oxidative and lipid metabolism in adipose tissue of 3′-azido-3-'deoxythymidine-treated rats. Antimicrob Agents Chemother 2007; 51: 583–590.

43.

Lynx

M.D.

, McKee

E.E.

3′-Azido-3-'deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006; 72: 239–243.

44.

Susan-Resiga

, Bentley

A.T.

, Lynx

M.D.

, LaClair

D.D.

, McKee

E.E.

Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart. Antimicrob Agents Chemother 2007; 51: 1142–1149.

45.

Sutinen

, Walker

U.A.

, Sevastianova

Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007; 12: 97–105.

46.

McComsey

G.A.

, Walker

U.A.

, Budhathoki

C.B.

Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS 2010; 24: 2507–2515.